These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34310081)

  • 1. The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease.
    Liu H; Deng B; Xie F; Yang X; Xie Z; Chen Y; Yang Z; Huang X; Zhu S; Wang Q
    Ann Clin Transl Neurol; 2021 Sep; 8(9):1917-1934. PubMed ID: 34310081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is white matter hyperintensity burden associated with cognitive and motor impairment in patients with parkinson's disease? A systematic review and meta-analysis.
    Carvalho de Abreu DC; Pieruccini-Faria F; Son S; Montero-Odasso M; Camicioli R
    Neurosci Biobehav Rev; 2024 Jun; 161():105677. PubMed ID: 38636832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease.
    Mak E; Dwyer MG; Ramasamy DP; Au WL; Tan LC; Zivadinov R; Kandiah N
    J Neuroimaging; 2015; 25(5):754-60. PubMed ID: 25753576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease.
    Sunwoo MK; Jeon S; Ham JH; Hong JY; Lee JE; Lee JM; Sohn YH; Lee PH
    Eur J Neurol; 2014 Jun; 21(6):922-e50. PubMed ID: 24661277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periventricular white matter hyperintensity burden and cognitive impairment in early Parkinson's disease.
    Huang X; Wen MC; Ng SY; Hartono S; Chia NS; Choi X; Tay KY; Au WL; Chan LL; Tan EK; Tan LC
    Eur J Neurol; 2020 Jun; 27(6):959-966. PubMed ID: 32124496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White matter hyperintensities are not associated with cognitive decline in early Parkinson's disease - The DeNoPa cohort.
    Hanning U; Teuber A; Lang E; Trenkwalder C; Mollenhauer B; Minnerup H
    Parkinsonism Relat Disord; 2019 Dec; 69():61-67. PubMed ID: 31678722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. White matter hyperintensities in cognitive impairment with Lewy body disease: a multicentre study.
    Gan J; Shi Z; Liu S; Li X; Liu Y; Zhu H; Shen L; Zhang G; Lu H; Gang B; Chen Z; Ji Y
    Eur J Neurol; 2023 Dec; 30(12):3711-3721. PubMed ID: 37500565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of white matter hyperintensity on cognitive function in PD patients: a meta-analysis.
    Zhao W; Cheng B; Zhu T; Cui Y; Shen Y; Fu X; Li M; Feng Y; Zhang S
    Front Neurol; 2023; 14():1203311. PubMed ID: 37621858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinson's Disease.
    Lee YH; Lee WJ; Chung SJ; Yoo HS; Jung JH; Baik K; Sohn YH; Seong JK; Lee PH
    J Parkinsons Dis; 2021; 11(1):239-249. PubMed ID: 33074193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia.
    Dadar M; Manera AL; Ducharme S; Collins DL
    Neurobiol Aging; 2022 Mar; 111():54-63. PubMed ID: 34968832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status.
    Shin J; Choi S; Lee JE; Lee HS; Sohn YH; Lee PH
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):315-21. PubMed ID: 22228726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.
    Dadar M; Zeighami Y; Yau Y; Fereshtehnejad SM; Maranzano J; Postuma RB; Dagher A; Collins DL
    Neuroimage Clin; 2018; 20():892-900. PubMed ID: 30292088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. White matter hyperintensity distribution differences in aging and neurodegenerative disease cohorts.
    Dadar M; Mahmoud S; Zhernovaia M; Camicioli R; Maranzano J; Duchesne S;
    Neuroimage Clin; 2022; 36():103204. PubMed ID: 36155321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes.
    Shen Y; Dong ZF; Pan PL; Xu G; Huang JY; Liu CF
    Neurol Sci; 2019 Sep; 40(9):1855-1863. PubMed ID: 31055730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease.
    González-Redondo R; Toledo J; Clavero P; Lamet I; García-García D; García-Eulate R; Martínez-Lage P; Rodríguez-Oroz MC
    Eur J Neurol; 2012 Aug; 19(8):1100-7. PubMed ID: 22360775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of age-related white matter hyperintensity with brain atrophy and cognitive impairment in patients with Parkinson's disease].
    Chen HM; Zhang MM; Wang YL
    Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(43):3397-3401. PubMed ID: 33238668
    [No Abstract]   [Full Text] [Related]  

  • 17. White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson's disease: results from the Ontario Neurodegenerative Diseases Research Initiative.
    Carvalho de Abreu DC; Pieruccini-Faria F; Sarquis-Adamson Y; Black A; Fraser J; Van Ooteghem K; Cornish B; Grimes D; Jog M; Masellis M; Steeves T; Nanayakkara N; Ramirez J; Scott C; Holmes M; Ozzoude M; Berezuk C; Symons S; Mohammad Hassan Haddad S; Arnott SR; Binns M; Strother S; Beaton D; Sunderland K; Theyers A; Tan B; Zamyadi M; Levine B; Orange JB; Roberts AC; Lou W; Sujanthan S; Breen DP; Marras C; Kwan D; Adamo S; Peltsch A; Troyer AK; Black SE; McLaughlin PM; Lang AE; McIlroy W; Bartha R; ; Montero-Odasso M
    Eur J Neurol; 2023 Apr; 30(4):920-933. PubMed ID: 36692250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study.
    Nicoletti A; Luca A; Baschi R; Cicero CE; Mostile G; Davì M; La Bianca G; Restivo V; Zappia M; Monastero R
    J Neurol; 2021 Feb; 268(2):549-558. PubMed ID: 32865628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson's disease.
    Stojkovic T; Stefanova E; Soldatovic I; Markovic V; Stankovic I; Petrovic I; Agosta F; Galantucci S; Filippi M; Kostic V
    J Neurol; 2018 Jun; 265(6):1320-1327. PubMed ID: 29572571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Scamarcia PG; Agosta F; Spinelli EG; Basaia S; Stojković T; Stankovic I; Sarasso E; Canu E; Markovic V; Petrović I; Stefanova E; Pagani E; Kostic VS; Filippi M
    Mov Disord; 2022 Feb; 37(2):315-324. PubMed ID: 34806799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.